Conditions: Schizophrenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 460
Healthy volunteers: no

Brief summary:
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

Detailed description:

Arms:
arm 1: SM-13496 40 mg was administered orally once daily. arm 2: SM-13496 80mg was administered orally once daily. arm 3: Placebo was administered orally twice daily. arm 4: Risperidone was administered orally twice daily.

Interventions: intervention 1: SM-13496 (lurasidone HCl) intervention 2: SM-13496 (lurasidone HCl) intervention 3: Placebo intervention 4: Risperidone
Intervention descriptions: intervention 1: Lurasidone HCl: 40 mg/day intervention 2: Lurasidone HCl: 80 mg/day intervention 3: None intervention 4: None

Protocol document: